about
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Clinical use of systemic IL-12 therapy.
@ast
Clinical use of systemic IL-12 therapy.
@en
Clinical use of systemic IL-12 therapy.
@nl
type
label
Clinical use of systemic IL-12 therapy.
@ast
Clinical use of systemic IL-12 therapy.
@en
Clinical use of systemic IL-12 therapy.
@nl
prefLabel
Clinical use of systemic IL-12 therapy.
@ast
Clinical use of systemic IL-12 therapy.
@en
Clinical use of systemic IL-12 therapy.
@nl
P2093
P1476
Clinical use of systemic IL-12 therapy.
@en
P2093
P304
P577
2001-01-01T00:00:00Z